The DOI matches its Crossref record; 435 of the 435 references it cites were found in a registry or an index.
Modulating ROS to overcome multidrug resistance in cancer
Abstract
The successful treatment of cancer has significantly improved as a result of targeted therapy and immunotherapy. However, during chemotherapy, cancer cells evolve and can acquire "multidrug resistance" (MDR), which significantly limits the efficacy of cancer treatment and impacts patient survival and quality of life. Among the approaches to reverse MDR, modulating reactive oxidative species (ROS) may represent a strategy to kill MDR cancer cells that are mechanistically diverse. ROS in cancer cells play a central role in regulating and inducing apoptosis, thereby modulating cancer cells proliferation, survival and drug resistance. The levels of ROS and the activity of scavenging/anti-oxidant enzymes in drug resistant cancer cells are typically increased compared to non-MDR cancer and normal cells. Consequently, MDR cancer cells may be more susceptible to alterations in ROS levels. Numerous studies suggest that compounds modulating cellular ROS levels can enhance MDR cancer cell death and sensitize MDR cancer cells to certain chemotherapeutic drugs. In the current review, we discuss the critical and targetable redox-regulating enzymes, including mitochondrial electron transport chain (ETC) complexes, NADPH oxidases (NOXs), enzymes related to glutathione metabolism, glutamate/cystine antiporter xCT, thioredoxin reductases (TrxRs), nuclear factor erythroid 2-related factor 2 (Nrf2), and their roles in regulating cellular ROS levels, drug resistance as well as their clinical significance. We also discuss and summarize the findings in the past decade regarding the efficacy of ROS modulators for the treatment of MDR cancer alone or as sensitizing compounds. Compounds that are efficacious in modulating ROS generation represent a prominent class of drug candidates that warrants evaluation in clinical trials for patients harboring MDR cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 401–435 of 435
Yen, H., Li, S.-H., Majima, H. J., Huang, Y.-H., Chen, C.-P., Liu, C., Tu, Y., & Chen, C. (2011) · Free Radical Research · doi:10.3109/10715762.2011.572969 · Cited by 24
Takayama, T., Kubo, T., Morikawa, A., Morita, T., Nagano, O., & Saya, H. (2016) · Medical Oncology · doi:10.1007/s12032-016-0760-x · Cited by 24
A Novel Agent Enhances the Chemotherapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells
Wang, L., Chan, J. Y., Zhou, X., Cui, G., Yan, Z., Wang, L., Yan, R., Di, L., Wang, Y., Hoi, M. P. M., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00249 · Cited by 24
Chew, S. H., Okazaki, Y., Akatsuka, S., Wang, S., Jiang, L., Ohara, Y., Ito, F., Saya, H., Sekido, Y., & Toyokuni, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.02.011 · Cited by 24
Park, G. B., Jeong, J., & Kim, D. (2017) · Oncology Letters · doi:10.3892/ol.2017.7255 · Cited by 24
PEITC reverse multi‐drug resistance of human gastric cancer SGC7901/DDP cell line
Tang, T., Song, X., Liu, Y., & Wang, W. (2013) · Cell Biology International · doi:10.1002/cbin.10169 · Cited by 23
Wu, L., Zhao, J., Cao, K., Liu, X., Cai, H., Wang, J., Li, W., & Chen, Z. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0217-2 · Cited by 23
Self-citationPeng, D., Hu, T., Soutto, M., Belkhiri, A., & El-Rifai, W. M. (2014) · Journal of Cancer · doi:10.7150/jca.9215 · Cited by 22
Li, W., Lam, W. S., Liu, K.-C., Wang, C., Chang, H. C., Jen, Y. C., Hsu, Y.-T., Shivatare, S. S., & Jao, S. (2009) · Organic Letters · doi:10.1021/ol902298s · Cited by 22
Nishimoto, S., Suzuki, T., Koike, S., Yuan, B., Takagi, N., & Ogasawara, Y. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.06.017 · Cited by 22
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.
Fan, R., Wang, Y., Wang, Y., Li, W., & Zheng, W. (2017) · PubMed · Cited by 22
Imai, K., Fukuda, T., Wada, T., Kawanishi, M., Tasaka, R., Yasui, T., & Sumi, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.6212 · Cited by 22
Mahbub, A. A., Maitre, C. L. L., Haywood‐Small, S., Cross, N. A., & Jordan, N. (2017) · Oncotarget · doi:10.18632/oncotarget.20501 · Cited by 22
Nunokawa, T., Yokogawa, N., Shimada, K., Sugii, S., Nishino, J., Gosho, M., Wagatsuma, Y., & Tohma, S. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.05.013 · Cited by 22
Wilde, F., Lemmerhirt, H., Emmrich, T., Bednarski, P. J., & Link, A. (2014) · Molecular Diversity · doi:10.1007/s11030-013-9501-7 · Cited by 21
Miller, R. C., Petereit, D. G., Sloan, J. A., Liu, H., Martenson, J. A., Bearden, J. D., Sapiente, R. A., Seeger, G. R., Mowat, R. B., Liem, B., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.01.063 · Cited by 21
Stojković, S., Podolski-Renić, A., Dinić, J., Stanković, T., Banković, J., Hadžić, S., Paunović, V., Isaković, A., Tanić, N., & Pešić, M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.05.018 · Cited by 20
Dai, L., Noverr, M. C., Parsons, C. H., Kaleeba, J. A. R., & Qin, Z. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00120 · Cited by 20
Oerlemans, R., Vink, J., Dijkmans, B. A. C., Assaraf, Y. G., van Miltenburg, M., van der Heijden, J., Ifergan, I., Lems, W. F., Scheper, R. J., Kaspers, G. J. L., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.060509 · Cited by 20
Self-citationSong, Y., Guo, X., Zheng, B., Liu, X., Dong, X., Yu, L., & Cheng, Y. (2011) · Toxicology in Vitro · doi:10.1016/j.tiv.2011.03.002 · Cited by 19
Wang, H., Jin, X., Zheng, J.-F., Wang, F., Dai, F., & Zhou, B. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.034 · Cited by 19
Xue, M., Cheng, J., Zhao, J., Zhang, S., Jian, J., Qiao, Y., & Liu, B. (2018) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12928 · Cited by 18
Oxidative degradation pathways of cellular DNA: product formation and mechanistic insights
Cadet, J. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.10.598 · Cited by 17
Correct Assay of Complex I Activity in Human Skin Fibroblasts by Timely Addition of Rotenone
de Wit, L. E. A., Scholte, H. R., & Sluiter, W. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.104802 · Cited by 16
Chen, S., Jiao, J. W., Sun, K. X., Zh, Z., & Zhao, Y. (2015) · Dove Medical Press (Taylor and Francis Group) · Cited by 16
Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.
Zhou, J., Shen, W., He, X., Qian, J., Liu, S., & Yu, G. (2015) · PubMed Central · Cited by 12
Overview of Glutathione Function and Metabolism
Will, Y. (1999) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx0601s00 · Cited by 11
Kengen, J., Deglasse, J.-P., Neveu, M.-A. C., Mignion, L., Desmet, C. M., Gourgue, F., Jonas, J., Gallez, B., & Jordan, B. F. (2018) · Free Radical Research · doi:10.1080/10715762.2018.1427236 · Cited by 11
Phenethyl isothiocyanate enhances TRAIL-induced apoptosis in oral cancer cells and xenografts
Yeh, C., Ko, H., Hsieh, Y., Wu, K., Kuo, M. Y., & Deng, Y. (2016) · Clinical Oral Investigations · doi:10.1007/s00784-016-1736-0 · Cited by 10
Evaluation of the in vitro Inhibitory Impact of Hypericin on Placental Glutathione S-Transferase pi
Dalmızrak, Ö., Kulaksiz-Erkmen, G., & Özer, N. (2012) · The Protein Journal · doi:10.1007/s10930-012-9433-6 · Cited by 9
Nrf-2/Gst-α mediated imatinib resistance through rapid 4-HNE clearance
Wang, X., Li, Y., Chen, W., Wang, Y., Hui, L., Liu, J., Li, N., Zhang, L., Zou, Y., & Wang, F. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.004 · Cited by 9
Yamaguchi, H., Kidachi, Y., Kamiie, K., Noshita, T., Umetsu, H., Fuke, Y., & Ryoyama, K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.008 · Cited by 8
He, T., Hatem, E., Vernis, L., et al. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.10.583 · Cited by 7
Qin, Q., Ma, P., Kuang, X., Gao, M., Mo, D.-H., Xia, S., Jin, N., Xia, J., Qi, Z., & Lin, C.-W. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.033 · Cited by 6
Harjes, U. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2018.22 · Cited by 5
Cited by
Biomedicine Meets Fenton Chemistry
Tang, Z., Zhao, P., Wang, H., Liu, Y., & Bu, W. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00977 · Cited by 745
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
The interaction between ferroptosis and lipid metabolism in cancer
Li, D., & Li, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00216-5 · Cited by 703
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
NAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 517
Metadata
- Authors
- Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 41
- Pages
- 1-25
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2901265038
- Cited by
- 661
- References
- 435
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.